Distinguished by the experience and knowledge of our scientists and technicians, PsychoGenics stands as a leading partner in preclinical Huntington’s disease studies.
Huntington’s disease arises from an unstable expansion of CAG repeats within the gene encoding the huntingtin (Htt) protein. This genetic anomaly results in an excessive accumulation of glutamine repeats, forming aggregates in the nucleus that contribute to the progressive nature of the disease. This devastating neurodegenerative disorder is characterized by abnormal motor movements, personality changes, and premature death.
Our Huntington’s Disease Models
Our preclinical Huntington’s disease research expertise encompasses the leading mouse models for drug discovery and development in the field:
Advancing Knowledge, Igniting Innovation in Preclinical Huntington’s Disease Research
At PsychoGenics, our preclinical research expertise and utilization of advanced animal models drive our work to advance your breakthrough Huntington’s disease therapy. Through detailed analysis of this disorder, we aim to contribute to the development of your innovative therapy and improve the lives of those affected.
Explore our areas of neurodegenerative disease specialization: